Filing scope and business context
The supplied filing is Galapagos NV’s Form 20-F for the fiscal year ended December 31, 2021, not Lakefront Biotherapeutics NV or a quarterly filing. The company is a Belgium-based integrated biopharmaceutical company reporting under IFRS in euros. Its principal commercial product is Jyseleca (filgotinib), approved for rheumatoid arthritis in the EU, Great Britain and Japan, and for ulcerative colitis in the EU and Great Britain.
During 2021, Galapagos assumed primary European commercialization, manufacturing and marketing-authorization responsibilities for Jyseleca from Gilead. The company also continued clinical development of filgotinib in Crohn’s disease and advanced programs including GLPG3667, GLPG4399, GLPG4716 and GLPG2737.
Financial performance and liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Total net revenues | €484.8 million | €478.1 million | +1% |
| Product net sales | €14.8 million | €2 thousand | New commercial contribution |
| Collaboration revenues | €470.1 million | €478.1 million | -2% |
| Operating loss | €165.6 million | €178.6 million | Loss narrowed 7% |
| Net loss | €103.2 million | €305.4 million | Loss narrowed 66% |
| Loss per share | €1.58 | €4.69 | Improved |
| Cash flow from operating activities | (€503.8 million) | (€427.3 million) | Higher cash use |
| Operational cash burn | €564.8 million | €517.4 million | Higher cash use |
| Cash and cash equivalents | €2.233 billion | €2.143 billion | +€90.3 million |
| Current financial investments | €2.470 billion | €3.026 billion | -€556.5 million |
| Cash and current financial investments | €4.703 billion | €5.169 billion | -€466.2 million |
| Long-term debt | No long-term debt other than lease liabilities | — | — |
Research and development expense was €491.7 million, down 6% year over year, primarily because of the winding down of ziritaxestat, MOR106 and GLPG1972 programs. Filgotinib R&D spending increased to €171.2 million from €126.9 million. Sales and marketing expense increased 5% to €70.0 million as the European commercial organization was built, while general and administrative expense increased 19% to €140.9 million.
Other financial income was €70.5 million, including €60.7 million of currency exchange gains, largely reflecting U.S.-dollar cash holdings. The company reported €53.7 million of other operating income, including €44.9 million of research and development incentives and €7.3 million of grants.
Material changes versus the prior comparable period
- Jyseleca product sales increased from €2 thousand to €14.8 million following the European commercial transition.
- Collaboration revenue remained the dominant revenue source and declined modestly. Revenue included €433.9 million from recognition of upfront payments and license fees, €32.4 million of milestone revenue and €3.8 million of royalties.
- Operating and net losses narrowed, partly because of lower R&D spending and substantially lower financial expenses. The 2020 period included a €105.7 million net foreign-exchange loss compared with a €56.5 million net exchange gain in 2021.
- Operating cash burn increased to €564.8 million from €517.4 million, despite the reported net loss improvement.
- Galapagos sold Fidelta on January 4, 2021 for €37.1 million, recognizing a €22.2 million gain. Fidelta is reported as discontinued operations.
- Gilead paid €110 million in 2021 under the amended filgotinib arrangement; an additional €50 million was expected in 2022, subject to contractual adjustments.
- Management initiated a €150 million full-year cost-savings program in 2021 and stated that more than half of the targeted savings had been realized during the year.
Guidance, outlook, risks and unusual items
- No precise 2022 revenue, earnings or cash-burn guidance is provided in the supplied filing. Management expects significant operating losses and substantial research, development and commercialization spending for the foreseeable future.
- Management stated that existing cash and current financial investments should fund operating expenses and capital expenditures for at least 12 months, and elsewhere described funding capacity as extending for the coming years under current assumptions. Additional capital may nevertheless be required.
- The DIVERSITY Phase 3 Crohn’s disease study enrolled 1,374 patients, with topline results anticipated in the first half of 2023. Galapagos assumed sponsorship and became responsible for all related development costs from April 1, 2022; Gilead committed to a one-time $15 million payment upon completion of the transfer.
- European commercialization economics transferred to Galapagos from January 1, 2022, subject to royalties to Gilead of 8% to 15% of European net sales beginning in 2024. These royalties may decline to 5.6% to 10.5% if filgotinib is approved in Europe for Crohn’s disease based on DIVERSITY data.
- Filgotinib remains exposed to class-wide JAK safety concerns, including potential cardiovascular events, cancer, blood clots and death. The EMA was conducting a safety review of JAK inhibitors, and filgotinib carried additional-monitoring status in Great Britain.
- The FDA issued a complete response letter for filgotinib in the United States, and Gilead and Galapagos elected not to pursue U.S. approval for rheumatoid arthritis.
- The company relies heavily on Gilead for collaboration funding, non-European commercialization and future milestones and royalties. Substantial revenue is concentrated in the Gilead relationship.
- Management identified a material weakness in internal control over financial reporting involving review of cost-to-complete estimates used in the percentage-of-completion method for filgotinib collaboration revenue. Deloitte issued an adverse opinion on internal control over financial reporting, although it issued an unqualified opinion on the financial statements.
- Unusual 2021 items included a €9.3 million impairment related to reassessment of the Mechelen headquarters construction project, €60.7 million of currency exchange gains and a €22.2 million gain on the Fidelta disposal.
- Purchase commitments totaled €369.9 million, including €212.1 million due within one year. The company also had €369.9 million of contractual filgotinib cost-sharing commitments.
- The filing states that Galapagos believed it was a passive foreign investment company for U.S. federal income-tax purposes in 2021, which may create adverse tax consequences for certain U.S. holders.
Investor verification points
- Verify the issuer and period: the source is Galapagos NV’s FY2021 Form 20-F, not Lakefront Biotherapeutics NV or “2021 Q4.”
- Reconcile collaboration revenue recognition, particularly the €235.7 million recognized for the filgotinib performance obligation and the €604.9 million deferred balance remaining at year-end.
- Assess the material weakness remediation and the sensitivity of 2021 revenue to cost-to-complete estimates; a 5% increase in estimated remaining costs would have reduced 2021 revenue by approximately €16.7 million.
- Evaluate Jyseleca’s European sales trajectory, reimbursement coverage, pricing, market share and the effect of assuming all European commercialization costs from 2022.
- Monitor DIVERSITY and other clinical results, regulatory decisions, JAK-class safety reviews and any changes to filgotinib labeling or dosing.
- Review dependence on Gilead, including the remaining milestone and royalty rights, European royalty obligations, Gilead’s 25.49% ownership and the outstanding warrant arrangements.
- Assess the cash runway against the €564.8 million 2021 operational cash burn, €369.9 million of purchase commitments and potential additional clinical and commercialization costs.
- Confirm the tax treatment of the company’s PFIC status for the relevant U.S. holder and tax year.